Thanks for Joining Us
San Antonio Breast Cancer Symposium®
December 7-10, 2021
RxPONDER at SABCS 2021

Highlights of SABCS

Dr. Christy Russell (VP, US Medical Affairs at Exact Sciences) reviews new data presented at SABCS 2021 and their implications for clinical management of breast cancer patients. Included is an in-depth discussion of the latest data from the landmark RxPONDER trial.

RxPONDER Clinical Trial Key Findings1

At SABCS 2020, Kevin Kalinsky, MD presented early RxPONDER data.

  • The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy

RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients


Learn more on RxPONDER
REFERENCES

  1. Kalinsky et al. Oral Presentation [GS3-00]. SABCS. 2020.

 
I agree to be contacted at the email provided above for marketing purposes and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.*

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.®